Imaging3,Inc. Receives FDA Approval to Distribute the Dominion Vi Scanner Under FDA (IDE) Regulations

Imaging3,Inc. Receives FDA Approval to Distribute the Dominion Vi Scanner Under FDA (IDE) Regulations.

  • Share ThisShareThis Email Contact Email PDF Version PDF Printer Friendly Version Print
Quote startThis approval to distribute the Dominion Vi Scanner is for investigational purposes only allowing the company to glean clinical imagery and functionality during the FDA 510(k) approval process. The Company is excited with this news and in anticipation of full FDA approval in the near future.Quote end

Burbank, CA (PRWEB) April 7, 2008

Imaging3™, Inc, (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, today provided insight into the Company's progress with the FDA. "This is a very important step in the FDA 510(k) approval process and is one step closer to full approval to market the Dominion Vi Scanner", stated Dean Janes, Chairman and CEO of Imaging3, Inc.

"This approval to distribute the Dominion Vi Scanner is for investigational purposes only allowing the company to glean clinical imagery and functionality during the FDA 510(k) approval process. The Company is excited with this news and in anticipation of full FDA approval in the near future.", stated Mr. Janes.

About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company's website at Imaging3, Inc.

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

###

Share:

Contact